Thermo Fisher Completes Strategic Acquisition of Clario Holdings
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Thermo Fisher ( (TMO) ) just unveiled an announcement.
On March 24, 2026, Thermo Fisher Scientific announced it had completed the $8.875 billion cash acquisition of Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, with additional deferred and performance-based payments possible. Clario will be integrated into Thermo Fisher’s Laboratory Products and Biopharma Services segment, expanding the company’s capabilities in digital collection, management and analysis of clinical trial endpoint data, a platform that has already supported about 70% of FDA and EMA novel drug approvals over the past decade.
Management described Clario as a strong strategic fit that strengthens Thermo Fisher’s position as a trusted partner to pharma and biotech customers by enabling faster, better-informed drug development decisions through advanced technology and data intelligence. Thermo Fisher highlighted Clario’s high growth and strong margin profile, expecting double-digit internal rates of return, high single-digit revenue growth, accretion to adjusted operating margin and adjusted EPS in the first year, and approximately $175 million in adjusted operating income from synergies by year five, underscoring the deal’s significance for shareholders and the company’s broader biopharma services strategy.
The most recent analyst rating on (TMO) stock is a Buy with a $670.00 price target. To see the full list of analyst forecasts on Thermo Fisher stock, see the TMO Stock Forecast page.
Spark’s Take on TMO Stock
According to Spark, TipRanks’ AI Analyst, TMO is a Neutral.
The score reflects solid underlying fundamentals and supportive 2026 guidance (profitability, strong free cash flow, and expected organic/EPS acceleration), partly offset by weaker balance-sheet flexibility from higher leverage and a notably bearish technical picture. Valuation is also a headwind given the high P/E and very low dividend yield.
To see Spark’s full report on TMO stock, click here.
More about Thermo Fisher
Thermo Fisher Scientific Inc., headquartered in Waltham, Mass., is a global leader in serving science with annual revenue of more than $40 billion. The company provides innovative technologies, analytical instruments, laboratory products, diagnostics, and pharmaceutical services that support life sciences research, complex analysis, clinical diagnostics, and the development and manufacture of therapies through brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Its offerings are aimed at pharma and biotech companies, academic and government labs, and healthcare providers seeking to increase productivity, solve analytical challenges, and improve patient outcomes. By combining technologies, purchasing convenience and biopharma services, Thermo Fisher positions itself as a comprehensive partner across the drug development and manufacturing value chain, with a stated mission to help customers make the world healthier, cleaner and safer.
Average Trading Volume: 2,360,127
Technical Sentiment Signal: Sell
Current Market Cap: $177.6B
Find detailed analytics on TMO stock on TipRanks’ Stock Analysis page.
